Amgen Inc - AMGN STOCK NEWS

Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q2 2023, payable on June 8, 2023, to stockholders of record by May 18, 2023. This announcement highlights Amgen's commitment to returning value to shareholders while reflecting its strong market position. As a prominent player in biotechnology, Amgen's focus on innovative therapeutics aligns with its strategy of addressing high unmet medical needs. The company was recognized in 2022 for its commitment to sustainability and was named one of the 'World's Best Employers' by Forbes.

Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference on March 8, 2023, at 11:10 a.m. ET. The presentation will feature Murdo Gordon and Peter H. Griffith, executive vice presidents at Amgen. The event will be accessible via a live webcast for media, investors, and the public. Interested parties can find details on Amgen’s website under Investors, with the presentation archived for 90 days post-event. Amgen has been a pioneer in biotechnology since 1980, focusing on innovative therapies for serious illnesses and is recognized as one of the Dow Jones Industrial Average companies.

Amgen recently announced significant findings regarding its cholesterol-lowering therapies, Repatha (evolocumab) and olpasiran, at the American College of Cardiology's annual session (March 4-6, 2023, New Orleans). Data from the Phase 3 FOURIER and FOURIER-OLE studies showed that earlier and extended use of Repatha leads to a reduction in total cardiovascular events among patients with atherosclerotic cardiovascular disease (ASCVD). Furthermore, the Phase 2 OCEAN(a)-DOSE study demonstrated that olpasiran significantly reduces lipoprotein(a) levels regardless of baseline concentrations. Amgen also initiated the first LDL-C Action Summit to address challenges in cardiovascular care.

Amgen has launched the African American Heart Study, a collaboration with the Association of Black Cardiologists and Morehouse School of Medicine. This observational study aims to investigate the link between Lipoprotein(a) levels and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American participants across the U.S. Cardiovascular disease poses a heightened risk to African Americans, who are 30% more likely to die from heart disease than non-Hispanic whites. The study seeks to address the underrepresentation of African Americans in cardiovascular research and may provide insights for improving clinical trial diversity.

Amgen (NASDAQ:AMGN) is scheduled to present at the 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 10:40 a.m. ET. Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities, will lead the presentation. The event will be available via live webcast for media, investors, and the public.

Details and replay options will be found on Amgen's website under Investors. As a leading biotechnology firm, Amgen focuses on significant unmet medical needs and aims to enhance health outcomes through innovative therapies. The company is recognized in major indices, including the Dow Jones Industrial Average.

Amgen and AstraZeneca announced that the FDA has approved TEZSPIRE (tezepelumab-ekko) for self-administration in a pre-filled pen for patients aged 12 and older with severe asthma. TEZSPIRE is the only biologic without phenotype limitations for severe asthma, initially approved in December 2021. The decision was based on results from the PATHFINDER clinical trials, where 92% of participants successfully administered the treatment at home. TEZSPIRE is also approved in the EU and under review in other countries. Common adverse reactions include pharyngitis, arthralgia, and back pain. Amgen and AstraZeneca will collaborate to commercialize TEZSPIRE in North America.

Amgen recently made available the full transcript and audio replay of its 2022 fourth quarter and full year financial results webcast. This webcast showcases key developments in Amgen's business and provides insights into the company's performance. Interested parties can find the transcript and audio on Amgen's website under the Investors section. The audio will be archived for at least 90 days, allowing for convenient access to the information discussed during the event.

Amgen reported its Q4 2022 revenues at $6.8 billion, nearly unchanged from Q4 2021, with a 4% rise in product sales with 10% volume growth. For the full year, revenues reached $26.3 billion, a 1% increase, driven by a 2% rise in product sales. However, GAAP EPS fell 11% in Q4 to $3.00, despite a full-year increase of 18% to $12.11. Amgen anticipates total revenues between $26.0 billion and $27.2 billion in 2023, while excluding contributions from the acquisition of Horizon Therapeutics.

Amgen announced that AMJEVITA (adalimumab-atto), the first biosimilar to Humira, is now available in the U.S. Approved by the FDA in 2016, AMJEVITA offers a list price 55% lower than Humira. This biosimilar aims to enhance patient access and reduce healthcare costs while treating serious inflammatory diseases. With a history of use in over 300,000 patients across more than 60 countries, AMJEVITA is available in multiple forms. The launch aligns with Amgen's commitment to responsible pricing and patient support.